311 related articles for article (PubMed ID: 35115327)
1. Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors.
Zachova K; Jemelkova J; Kosztyu P; Ohyama Y; Takahashi K; Zadrazil J; Orsag J; Matousovic K; Galuszkova D; Petejova N; Mestecky J; Raska M
J Am Soc Nephrol; 2022 May; 33(5):908-917. PubMed ID: 35115327
[TBL] [Abstract][Full Text] [Related]
2. Sialylation of IgG inhibits the formation of galactose-deficient IgA1-containing immune complexes and protects mesangial cells from injury in IgA nephropathy.
Liu Y; Li H; Yu H; Wang F; Jia J; Yan T
BMC Nephrol; 2022 Jan; 23(1):25. PubMed ID: 35016642
[TBL] [Abstract][Full Text] [Related]
3. Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1.
Rizk DV; Saha MK; Hall S; Novak L; Brown R; Huang ZQ; Fatima H; Julian BA; Novak J
J Am Soc Nephrol; 2019 Oct; 30(10):2017-2026. PubMed ID: 31444275
[TBL] [Abstract][Full Text] [Related]
4. Immunostaining of galactose-deficient IgA1 by KM55 is not specific for immunoglobulin A nephropathy.
Zhao L; Peng L; Yang D; Chen S; Lan Z; Zhu X; Yuan S; Chen G; Liu Y; Liu H
Clin Immunol; 2020 Aug; 217():108483. PubMed ID: 32479989
[TBL] [Abstract][Full Text] [Related]
5. Increased binding of polymeric lambda-IgA to cultured human mesangial cells in IgA nephropathy.
Lai KN; To WY; Li PK; Leung JC
Kidney Int; 1996 Mar; 49(3):839-45. PubMed ID: 8648928
[TBL] [Abstract][Full Text] [Related]
6. Role of Epstein-Barr Virus in Pathogenesis and Racial Distribution of IgA Nephropathy.
Zachova K; Kosztyu P; Zadrazil J; Matousovic K; Vondrak K; Hubacek P; Julian BA; Moldoveanu Z; Novak Z; Kostovcikova K; Raska M; Mestecky J
Front Immunol; 2020; 11():267. PubMed ID: 32184780
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of Serum Galactose-Deficient IgA1 Level in Children with IgA Nephropathy.
Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Ohta K; Yachie A
J Immunol Res; 2020; 2020():4284379. PubMed ID: 32537466
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy.
Zhao YF; Zhu L; Liu LJ; Shi SF; Lv JC; Zhang H
BMC Nephrol; 2017 Sep; 18(1):301. PubMed ID: 28969604
[TBL] [Abstract][Full Text] [Related]
9. Increased sialylation of polymeric lambda-IgA1 in patients with IgA nephropathy.
Leung JC; Tang SC; Chan DT; Lui SL; Lai KN
J Clin Lab Anal; 2002; 16(1):11-9. PubMed ID: 11835525
[TBL] [Abstract][Full Text] [Related]
10. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases.
Yanagawa H; Suzuki H; Suzuki Y; Kiryluk K; Gharavi AG; Matsuoka K; Makita Y; Julian BA; Novak J; Tomino Y
PLoS One; 2014; 9(5):e98081. PubMed ID: 24858067
[TBL] [Abstract][Full Text] [Related]
11. Light-chain composition of serum IgA1 and in vitro IgA1 production in IgA nephropathy.
Chen N; Nusbaum P; Halbwachs-Mecarelli L; Lesavre P
Nephrol Dial Transplant; 1991; 6(11):846-50. PubMed ID: 1775249
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy.
Zhang K; Li Q; Zhang Y; Shang W; Wei L; Li H; Gao S; Yan T; Jia J; Liu Y; Lin S
Kidney Blood Press Res; 2019; 44(5):1196-1206. PubMed ID: 31574506
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.
Wada Y; Matsumoto K; Suzuki T; Saito T; Kanazawa N; Tachibana S; Iseri K; Sugiyama M; Iyoda M; Shibata T
PLoS One; 2018; 13(11):e0206865. PubMed ID: 30388165
[TBL] [Abstract][Full Text] [Related]
14. Phosphatase control of cytokine-mediated overproduction of galactose-deficient IgA1, the main autoantigen in IgA nephropathy.
Reily C; Rice T; Crossman DK; Rizk DV
J Autoimmun; 2022 Oct; 132():102883. PubMed ID: 35987175
[TBL] [Abstract][Full Text] [Related]
15. Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1.
Ebefors K; Liu P; Lassén E; Elvin J; Candemark E; Levan K; Haraldsson B; Nyström J
BMC Nephrol; 2016 Apr; 17():40. PubMed ID: 27044423
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of aberrantly expressed profiles of mRNA and its relationship with serum galactose-deficient IgA1 level in IgA nephropathy.
Liu Y; Liu X; Jia J; Zheng J; Yan T
J Transl Med; 2019 Sep; 17(1):320. PubMed ID: 31547815
[TBL] [Abstract][Full Text] [Related]
17. Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy.
Nihei Y; Suzuki H; Suzuki Y
Front Immunol; 2023; 14():1165394. PubMed ID: 37114051
[TBL] [Abstract][Full Text] [Related]
18. Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?
Suzuki H; Allegri L; Suzuki Y; Hall S; Moldoveanu Z; Wyatt RJ; Novak J; Julian BA
Dis Markers; 2016; 2016():7806438. PubMed ID: 27647947
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression.
Elíasdóttir S; Khramova A; Saeed A; Guron G; Boi R; Mölne J; Ebefors K; Nyström J
BMC Nephrol; 2023 Jun; 24(1):160. PubMed ID: 37286948
[TBL] [Abstract][Full Text] [Related]
20. LPS/TLR4 Pathway Regulates IgA1 Secretion to Induce IgA Nephropathy.
He H; Shen M; Tang Y; Sun W; Xu X
Altern Ther Health Med; 2024 Jan; 30(1):419-425. PubMed ID: 37820669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
